Last updated: May 28, 2026
KORSUVA suppliers: Who manufactures and supplies Korsuva (imlifidase) for FDA distribution and global markets?
KORSUVA is the brand name for imlifidase. Direct, authoritative supplier identification requires public sourcing that links the product’s listed manufacturer(s) and distributor(s) to KORSUVA’s specific drug product (NDC), labeling, and FDA product record.
No complete, citable supplier roster (manufacturing sites, labeler/distributor entries, and country-by-country supply channels) is available in the provided information, so a complete supplier list cannot be produced to a litigation-grade standard.
What companies supply KORSUVA (imlifidase) to wholesalers and hospitals in the US?
A correct US supplier answer depends on the FDA NDC labeler/distributor and drug substance/drug product manufacturing entries for the specific KORSUVA NDC. Without the NDC-to-labeler mapping and the corresponding FDA product record, a supplier list would be incomplete or potentially incorrect.
What is the Orange Book status of KORSUVA and how does it affect supply visibility?
KORSUVA’s exclusivity and patent status affect generic competition risk, not manufacturing supply. Supplier identification still requires the FDA product listing (labeler/manufacturer) and commercial distributor.
Which KORSUVA distributors appear on US packaging?
Distributor identity typically aligns to the labeler on the FDA listing and the company printed on the package label. That mapping is not provided here.
Who manufactures the drug substance and finished dosage for KORSUVA?
A defensible supplier profile normally separates:
- Drug substance manufacturer (API manufacturer and site)
- Finished drug product manufacturer (fill/finish and final dosage form site)
- Contract manufacturing partners shown on CMC sections or public labeling documents
No manufacturer/site data is provided, so a finished supplier list cannot be constructed.
Which contract manufacturers make imlifidase for KORSUVA?
Contract partner identification requires public CMC or labeling references that list manufacturing sites or licensors. This is not included in the input.
Which countries supply KORSUVA and what are the local market partners?
Country-by-country supply depends on:
- Marketing authorization holders
- Local distribution agreements
- Importer-of-record entities
- Tender supply arrangements for hospitals
No jurisdictional distribution data is provided, so an accurate global supplier mapping cannot be produced.
How does KORSUVA supply chain structure compare with other solid-transplant or immunodepletion therapies?
Comparisons typically use:
- centralized biologics manufacturing
- specialized cold-chain distribution
- limited global distributors
This requires the supplier and packaging chain for KORSUVA itself, which is not provided.
What generic or biosimilar supplier risks exist for KORSUVA supply disruption?
KORSUVA is biologics-adjacent therapy (imlifidase). Supplier risk assessment depends on whether there are:
- authorized biosimilar candidates
- manufacturing redundancies
- supply agreements
Without KORSUVA’s supplier roster, disruption risk cannot be quantified.
Key Takeaways
- A litigation-grade supplier list for KORSUVA (imlifidase) requires publicly citable mappings from the FDA product listing (NDC labeler/distributor and manufacturer sites) and/or official labeling.
- The input contains no KORSUVA NDC or labeler/distributor/manufacturer data, so a complete and accurate supplier roster cannot be produced.
FAQs
- What does “labeler” mean for KORSUVA supply?
- How can I identify KORSUVA’s manufacturer from its NDC?
- Do KORSUVA distributors differ from the marketing authorization holder by country?
- What documents usually list imlifidase manufacturing sites for KORSUVA?
- Does KORSUVA supply rely on multiple contract manufacturing sites or a single platform?
References (APA)
No sources were provided or cited.
